NICE Javlor ''torture'' could have international ripple effect
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has again decided that there is not enough conclusive evidence to recommend Pierre Fabre's Javlor (vinflunine) for treating bladder cancer after prior platinum treatment has failed. The decision is a disaster and other markets as far afield as Mexico could take up the decision too, said Martin Grange, Pierre Fabre's UK managing director. "The impact NICE has on the world is devastating," he said.
You may also be interested in...
Scotland Recommends Interim Funding For Regeneron/Sanofi’s Libtayo
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
Meindert Boysen On What Companies Should Expect From NICE
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
Novartis ‘Urgently’ Working To Improve Zolgensma Access Program
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.
Need a specific report? 1000+ reports available
Buy Reports